Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Mol Cancer Res. 2017 Apr 25;15(8):984–997. doi: 10.1158/1541-7786.MCR-17-0063

Figure 6. Combined AurkA and pan-H3K9-HMT inhibition triggers uncoordinated checkpoint responses and reduces the centromeric H3K9me mark.

Figure 6

A) Combination of chaetocin and MLN8237 treatments triggered dysregulation of a variety of proteins involved in cellular checkpoint response. Protein levels were observed by western blot with α-tubulin illustrating equal loading of samples across all treatments. B) Pathway diagram illustrates the ATM/ATR-Chk1-p53 pathway for G2M cell arrest. Increases and decreases in nodes affected by the combination treatment are marked with red and green stars, respectively. C) Treatments synergize to reduce the H3K9me mark in cells. Total levels of H3K9me2 and H3K9me3 are indicated by western blot of the vehicle, chaetocin, MLN8237, and combination treatments of PDAC cells. D) Representative images of H3K9me3 immunofluorescence staining in L3.6 cells demonstrated a global decrease of H3K9me3 upon treatment with the combination of drugs. Scale=2000nm.